First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2613-2619

  Lindemann, K ^a   Christensen, R D ^b   Vergote, I ^c   Stuart, G ^d   Izquierdo, M A ^e   Kaern J ^a   Havsteen, H ^f   Eisenhauer, E ^g   Ridderheim, M ^h   Lopez, A B ⁱ   Hirte, H ^j   Aavall Lundquvist, E ^k   Vrdoljak, E ^l   Green, J ^m   Kristensen, G B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Catalán Hospital   (Spain)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g QUEEN S UNIVERSITY   (Canada)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j JURAVINSKI CANCER CENTRE   (Canada)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSITY HOSPITAL SPLIT   (Croatia)

^m CLATTERBRIDGE HOSPITAL   (United Kingdom)

more..

Author keywords

Epirubicin; Ovarian cancer; Phase III study; Platinum based chemotherapy; Survival; Toxicity

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTE; GRANULOCYTOPENIA; HEARING DISORDER; HEART LEFT VENTRICLE FUNCTION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 84867116493     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds060     Document Type: Article

References (23)

1. du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 (Suppl 8): viii7-viii12.
2. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992; 80: 954-960.
3. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-732.
4. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991; 9: 1668-1674.
5. Vermorken JB, Kobierska A, Chevallier B et al. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. Ann Oncol 2000; 11: 1035-1040.
6. Vermorken JB, ten Bokkel Huinink WW, Kobierska A et al. Phase I study of highdose epirubicin in platinum-pretreated patients with ovarian carcinoma. Oncology 1999; 57: 10-16.
7. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
8. Conte PF, Gennari A, Salvadori B et al. Paclitaxel plus epirubicin in advanced breast cancer. Oncology 1998; 12 (Suppl 1): 40-44.
9. Luck HJ, du Bois A, Thomssen C et al. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer. Oncology 1997; 11 (Suppl 3): 34-37.
10. Gehl J, Boesgaard M, Paaske T et al. Paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 1996; 23 (Suppl 15): 35-38.
11. du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127-1135.
12. National Cancer Institute. Common Toxicity Criteria (CTC). 2006; http://www.cancer.gov (19 April 2012, date last accessed).
13. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-580.
14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Handbook for Reporting Results of Cancer Treatment [Offset publication 40] Geneva, Switzerland: World Health Organization 1979.
16. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
17. Venturini M, Lunardi G, Del Mastro L et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000; 18: 2116-2125.
18. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425.
19. du Bois A, Herrstedt J, Hardy-Bessard AC et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28: 4162-4169.
20. Pfisterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98: 1036-1045.
21. Burger RA, Brady MF, Fleming GF et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
22. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
23. Ledermann J, Harter P, Gourley M et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSRSOC). J Clin Oncol 2011; 29 (Suppl): (Abstr 5003).